Other approaches to enhance the efficacy of TILs have included the introduction of the CXCR2 gene into tumor-specific T cells to enhance their tumor-specific migration, localization, and in turn anti-tumor response [75] as well as T cells genetically modified to resist exogenous TGF-β signaling, which is known to inhibit tumor-specific cellular immunity [76]. The gene discussed is TGFB1; the disease is neoplasm.